A clinical trial found that nanopharmaceutical drug CRLX101 is showing promise as a potential new treatment for cancers that develop resistance to antiangiogenic drugs and radiation therapy. The results of the trials were presented at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, held Oct. 19 - 23. Antiangiogenic drugs are anticancer drugs designed to cut off the blood supply that brings tumors the nutrients they need ...
via Medindia Health News
More READ
No comments:
Post a Comment